Thursday, 15 October 2026European Markets

SHELF DRILLING Stock Slides By 16% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of SHELF DRILLING (Oslo Børs Benchmark Index_GI: SHLF.OL) fell by a staggering 16.84% in 5 sessions from kr33.25 to kr27.65 at 19:39 EST on Wednesday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI is falling 3.74% to kr1,160.25, after five sequential sessions in a row of losses.

SHELF DRILLING's last close was kr29.50, 14.24% below its 52-week high of kr34.40.

About SHELF DRILLING

Shelf Drilling, Ltd., together with its subsidiaries, operates as a shallow water offshore drilling contractor in the Middle East, North Africa, the Mediterranean, Southeast Asia, India, and West Africa. The company offers equipment and services for the drilling, completion, maintenance, and decommissioning of oil and natural gas wells. It serves government owned or controlled energy companies, and publicly listed global integrated oil companies or independent exploration and production companies. As of December 31, 2021, it owned 30 independent-leg cantilever jack-up rigs. Shelf Drilling, Ltd. was incorporated in 2012 and is headquartered in Dubai, the United Arab Emirates.

Earnings Per Share

As for profitability, SHELF DRILLING has a trailing twelve months EPS of kr-16.75.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -19.14%.

More news about SHELF DRILLING (SHLF.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com